Astra faces probe in China; AbbVie, EvolveImmune ink potential US$ 1.4 bn deal; EC levies US$ 503 mn fine on Teva
In this week’s Phispers, AstraZeneca faces a major crisis in China as its president Leon Wang is under investigation in w...
Impressions : 1157
FDA releases GDUFA II fee for FY20; Teva to recover settlement charge from execs
This week, the USFDA released its GDUFA II user fee for fiscal 2020.
Unlike last year, when the fees were hiked significantly...
Impressions : 1690
GSK chairman to step down ahead of split; Novartis’ CEO shares updates on digital healthcare
This week, Phispers brings you news from two Indian companies — Sun Pharmaceuticals and Aurobindo Pharma.
While Sun is ...
Impressions : 3030
2017 closes with record approvals of generics, novel drugs; 2018 begins with reprieves for Teva
PharmaCompass wishes its readers a very happy new year. We begin the year with an analysis of 2017, when we saw record approval...
Impressions : 4381
- Privacy policy
- Terms and conditions
- Disclaimers
-
- Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.